CoChat

Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors.

Shapiro, G., LoRusso, P., Kwak, E. L., Cleary, J. M., Musib, L., Jones, C., de Crespigny, A., Belvin, M., McKenzie, M., Gates, M. R., Chan, I. T., Bendell, J. C. · 2011 · Journal of Clinical Oncology
Cited by 44

The DOI matches its Crossref record.

Abstract

3005^ Background: The RAS/RAF/MEK and PI3K/AKT signaling pathways are both deregulated in many tumor types. Targeting both pathways may be more efficacious than targeting either pathway alone. In preclinical models, concurrent administration of GDC‐0973, a potent, selective, MEK1/2 inhibitor and GDC-0941, a potent class I PI3K inhibitor, shows improved efficacy compared to either alone when these agents are dosed either continuously or intermittently. Methods: A phase Ib dose-escalation study with 3+3 design was initiated in patients (pts) with advanced solid tumors to evaluate the safety and pharmacokinetics (PK) of oral combination dosing of GDC-0973 and GDC-0941. Pts received once daily (QD) GDC-0973 + GDC-0941 on a 21 day on/7 day off (21/7) schedule or intermittent GDC-0973 on Days 1, 4, 8, 11, 15, 18 of a 28 day cycle + GDC-0941 QD on a 21/7 schedule. Initial doses were 20 mg GDC-0973 + 80 mg GDC-0941 on 21/7 schedule; 100 mg GDC-0973 + 130 mg GDC-0941 on intermittent schedule. Serial plasma PK samples, FDG-PET and CT scans were obtained. Results: 30 pts have enrolled - 27 pts in 6 cohorts on 21/7 schedule; 3 pts on intermittent schedule. DLTs were grade 3 lipase (n=1) and grade 4 CPK elevation (n=1). Adverse events related to study drug combination were diarrhea (90%; all G1/2), fatigue (61%; 50% G1/2, 11% G3), nausea (61%; all G1/2), rash (50%; 45% G1/2, 5% G3), vomiting (33%; all G1/2), decreased appetite (17%; all G1/2), and dysgeusia (17%; all G1/2). Preliminary analysis indicates PK of GDC-0973 or GDC-0941 are not altered when dosed in combination. 6 of 15 pts had an FDG-PET partial metabolic response at one or more timepoints. Decreases in RECIST measurable target lesions were seen in 5 pts: 2 with melanoma (-75%; -27%), 1 prostate cancer (-21%), and 2 NSCLC (-18%; -13%). 3 pts had prolonged stable disease > 6 months. Conclusions: Combination dosing of GDC‐0973 and GDC-0941 is generally well tolerated, with toxicities similar to those observed in single agent GDC-0973 and GDC-0941 phase I trials. There are early signs of anti-tumor activity. Dose escalation on both schedules continues and updated data will be presented.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2011.29.15_suppl.3005

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 44

Metadata

Authors
Shapiro, G., LoRusso, P., Kwak, E. L., Cleary, J. M., Musib, L., Jones, C., de Crespigny, A., Belvin, M., McKenzie, M., Gates, M. R., Chan, I. T., & Bendell, J. C.
Venue
Journal of Clinical Oncology
Published
2011-05-20
Volume
29
Issue
15_suppl
Pages
3005-3005
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2222368525
Cited by
44
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors. https://app.cochat.ai/papers/10.1200/jco.2011.29.15_suppl.3005
The paper
Shapiro, G., LoRusso, P., Kwak, E. L., Cleary, J. M., Musib, L., Jones, C., de Crespigny, A., Belvin, M., McKenzie, M., Gates, M. R., Chan, I. T., & Bendell, J. C. (2011). Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2011.29.15_suppl.3005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.